Foreign media: China’s innovative pharmaceuticals continue to enhance their global competitiveness, yet the country still lacks blockbuster drugs with sales comparable to top-selling Western medications. China aims to achieve at least five drugs generating over $1 billion in annual global revenue by 2030.
Multiple analysts believe this target is attainable: by the first half of 2026, Chinese biopharmaceutical companies are expected to account for more than 50% of global drug transaction volume. The share of globally first-in-class drugs developed independently in China has risen from 4% in 2016 to approximately 22% today, with a goal of exceeding 25% by 2030.
Zanubrutinib, developed by BeiGene, is already one of China’s drugs with annual sales surpassing $1 billion. It is used to treat blood cancers including mantle cell lymphoma and chronic lymphocytic leukemia by inhibiting the BTK enzyme, thereby impeding cancer cell proliferation.
Original source: toutiao.com/article/1878632395816000/
Disclaimer: The views expressed in this article are those of the author alone.